News | August 27, 2009

New Lung Cancer Staging System to Impact Treatment Decisions

August 27, 2009 - The just-released 7th edition of the TNM (tumor, node, metastases) staging system for lung cancer will profoundly impact treatment decisions and patients' eligibility for clinical trials.

One in six lung cancer patients will receive a different staging category based on the 7th edition of the TNM staging system, reported Dr. Peter Goldstraw, chair of the staging project of the International Association for the Study of Lung Cancer (IASLC), at the association's World Conference on Lung Cancer.

Highlights of the new staging system for non-small cell lung cancer (NSCLC) include the following:

- New subcategories of stage T1 (early-stage) disease are based on size: Tumors measuring 2 cm or smaller will now be classified as T1a, whereas tumors larger than 2 cm and up to 3 cm will be classified as T1b. T2 disease will also be subdivided into T2a (tumors larger than 3 cm and up to 5 cm) and T2b (tumors larger than 5 cm and up to 7 cm).

- A new category (T3) will be used to describe tumors larger than 7 cm.

- Patients previously considered T4 because of additional tumor nodules in the same lung as the primary tumor will now be classified as T3. If these patients are node negative, they will be considered to have stage IIB disease.

- Patients with additional tumor nodules in the bilateral lung (previously M1) will now receive a designation of T4, and they will be down-staged from stage IV to stage IIIA.

- The presence of malignant pleural effusions, long referred to by oncologists as "wet IIIBs" and treated as if the patient had disseminated disease, will now be officially staged that way, as stage IV disease.

- Specifically, pleural dissemination will no longer be classified T4, but will now fall into a new category (M1a), the same designation given when additional nodules are found in the contralateral lung.

- Distant metastases will be subclassified within M1 as M1b disease.

- Staging changes will include the reclassification of patients with T2b tumors (5-7 cm) who have node-negative disease to stage IIA.

- Patients with T3 tumors (larger than 7 cm) will be considered to have stage IIB disease if they are node negative, but stage IIIA if they have associated features of M1, listed above.

The "N" classification within TNM that describes the number of involved lymph nodes will remain unchanged in the 7th edition.

The revisions to the TNM system are based on multidisciplinary contributions from the world lung cancer community, drawing on data compiled from more than 100,000 lung cancer cases from 46 centers in 19 countries. The IASLC led the revision effort, but both the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) have accepted the recommendations.

For more information: www.iaslc.org

Related Content

Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...
Varian Showcases Cancer Care Systems and Software at AAPM 2019
News | Radiation Therapy | August 02, 2019
Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the...
Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect
News | Radiation Oncology | July 31, 2019
The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of...
Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation
News | Cardio-oncology | July 29, 2019
Cancer patients taking cholesterol-lowering statin medication following radiation therapy of the chest, neck or head...